SMMTSummit Therapeutics Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2M | $705K | $0 | $0 | — | |
| Operating income | −$86M | −$72M | −$610M | −$226M | — | |
| Net income | −$89M | −$79M | −$615M | −$221M | −$1.1B | 388% |
| Operating cash flow | −$73M | −$42M | −$77M | −$142M | −$323M | 127% |
| Capex | $306K | $624K | $128K | $139K | $657K | 373% |
| Stock-based comp | $13M | $12M | $14M | $51M | $732M | 1337% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 372 | 120 |
| FY2024 | — | — | 380 | 114 |
| FY2023 | — | — | 56 | 116 |
| FY2022 | — | — | 90 | 112 |
| FY2021 | — | — | 57 | 126 |